Last reviewed · How we verify
Cefmetazole (drug)
Cefmetazole is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.
Cefmetazole is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Surgical prophylaxis in abdominal and gynecological procedures, Treatment of intra-abdominal infections, Treatment of gynecological infections.
At a glance
| Generic name | Cefmetazole (drug) |
|---|---|
| Sponsor | National Taiwan University Hospital |
| Drug class | Second-generation cephalosporin |
| Target | Penicillin-binding proteins (PBPs) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Cefmetazole works by disrupting the cross-linking of peptidoglycan in bacterial cell walls, leading to cell wall instability and bacterial death. It has broad-spectrum activity against gram-positive and gram-negative bacteria, with enhanced activity against anaerobes compared to first-generation cephalosporins. The drug is typically used for surgical prophylaxis and treatment of intra-abdominal and gynecological infections.
Approved indications
- Surgical prophylaxis in abdominal and gynecological procedures
- Treatment of intra-abdominal infections
- Treatment of gynecological infections
Common side effects
- Hypersensitivity reactions
- Diarrhea
- Nausea
- Phlebitis at injection site
Key clinical trials
- Retrograde Intrarenal Surgery Low Risk Trial (PHASE4)
- Preventive Therapy of Postoperative Intra-abdominal Infection Based on Serum Lactate Changes (NA)
- Patients Response to Early Switch To Oral:Osteomyelitis Study (EARLY_PHASE1)
- Trial of Antibiotic Prophylaxis in Elective Laparoscopic Colorectal Surgery: Oral and Systemic Versus Systemic Antibiotics (PHASE3)
- The Effect of Periarticular Multi-Drug Regimen on Pain After Partial Hip Replacement (PHASE4)
- Trial of Antibiotic Prophylaxis in Elective Colorectal Surgery (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cefmetazole (drug) CI brief — competitive landscape report
- Cefmetazole (drug) updates RSS · CI watch RSS
- National Taiwan University Hospital portfolio CI